Servier Inks Glycoengineering Deal with kyron.bio

Servier inks glycoengineering deal with kyron.bio

The collaboration will leverage kyron.bio’s glycoengineering platform to optimise a specific antibody candidate selected by Servier.

kyron.bio Announces Strategic Partnership with Servier to Advance Precision Glycosylation in Antibody Therapeutics - Business News Week

Innovative glycobiology platform aimed at enhancing the efficacy, safety, and scalability of next-generation antibody therapeutics across multiple disease areas Paris, Mar 09 – kyron.bio, a biotechnology company pioneering precision glycoengineering for antibody therapeutic development, today announced a strategic partnership with Servier, an international pharmaceutical group governed by a Foundation. Under the terms of the agreement, […] The p…

kyron.bio teams up with Servier to test “precision glycosylation” as a new lever for antibody performance - European Biotechnology Magazine

Paris-based kyron.bio has signed a strategic partnership with French pharma group Servier to glycoengineer an antibody selected by Servier. This agreement marks an early proof-of-concept deal designed to show the company can reliably “dial in” a specific, pre-defined N-glycoform on a therapeutic antibody. The post kyron.bio teams up with Servier to test “precision glycosylation” as a new lever for antibody performance appeared first on European …